Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017

  • ID: 4311806
  • Report
  • 258 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • ArQule Inc
  • Blueprint Medicines Corp
  • Celldex Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Natco Pharma Ltd
  • MORE
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • ArQule Inc
  • Blueprint Medicines Corp
  • Celldex Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Natco Pharma Ltd
  • MORE
  1. Introduction
  2. Gastrointestinal Stromal Tumor (GIST) - Overview
  3. Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
  15. AB Science SA
  16. Advanced Accelerator Applications SA
  17. Advenchen Laboratories LLC
  18. Ariad Pharmaceuticals Inc
  19. Arog Pharmaceuticals Inc
  20. ArQule Inc
  21. Array BioPharma Inc
  22. Astex Pharmaceuticals Inc
  23. Blueprint Medicines Corp
  24. Boston Biomedical Inc
  25. Calithera Biosciences Inc
  26. Celldex Therapeutics Inc
  27. Chipscreen Biosciences Ltd
  28. CytRx Corp
  29. Deciphera Pharmaceuticals LLC
  30. Exelixis Inc
  31. F. Hoffmann-La Roche Ltd
  32. Hanmi Pharmaceuticals Co Ltd
  33. Horizon Pharma Plc
  34. Immunicum AB
  35. Jiangsu Hengrui Medicine Co Ltd
  36. Natco Pharma Ltd
  37. Nerviano Medical Sciences Srl
  38. Novartis AG
  39. Omeros Corp
  40. Pharma Mar SA
  41. Plexxikon Inc
  42. Rhizen Pharmaceuticals SA
  43. Taiho Pharmaceutical Co Ltd
  44. Gastrointestinal Stromal Tumor (GIST) - Drug Profiles
  45. aldoxorubicin hydrochloride - Drug Profile
  46. amcasertib - Drug Profile
  47. apatinib - Drug Profile
  48. ARQ-092 - Drug Profile
  49. binimetinib - Drug Profile
  50. BLU-285 - Drug Profile
  51. buparlisib hydrochloride - Drug Profile
  52. cabozantinib s-malate - Drug Profile
  53. CB-839 - Drug Profile
  54. CDX-0158 - Drug Profile
  55. CHMFLKIT-110 - Drug Profile
  56. crenolanib besylate - Drug Profile
  57. CS-2164 - Drug Profile
  58. dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
  59. DCC-2618 - Drug Profile
  60. everolimus - Drug Profile
  61. HM-95573 - Drug Profile
  62. interferon gamma-1b - Drug Profile
  63. Intuvax - Drug Profile
  64. masitinib - Drug Profile
  65. nilotinib - Drug Profile
  66. NMSP-088 - Drug Profile
  67. NRCAN-019 - Drug Profile
  68. onalespib - Drug Profile
  69. Peptide to Antagonize GRPR for Oncology - Drug Profile
  70. pexidartinib - Drug Profile
  71. PLX-9486 - Drug Profile
  72. PM-184 - Drug Profile
  73. ponatinib hydrochloride - Drug Profile
  74. SF-1126 - Drug Profile
  75. SHR-1020 - Drug Profile
  76. Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile
  77. Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
  78. TAS-116 - Drug Profile
  79. TGR-1202 - Drug Profile
  80. vemurafenib - Drug Profile
  81. WBZ-4 - Drug Profile
  82. Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
  83. Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
  84. Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
  85. Featured News & Press Releases
  86. Appendix
  87. Methodology
  88. Coverage
  89. Secondary Research
  90. Primary Research
  91. Expert Panel Validation
  92. Contact Us
  93. Disclaimer
List of Tables:
  1. Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  10. Number of Products by Stage and Mechanism of Action, H1
  11. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  12. Number of Products by Stage and Route of Administration, H1
  13. Number of Products by Stage and Molecule Type, H1
  14. Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1
  15. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1
  16. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1
  17. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1
  18. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1
  19. Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1
  20. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1
  21. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1
  22. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1
  23. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1
  24. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1
  25. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1
  26. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1
  27. Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1
  28. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1
  29. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1
  30. Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1
  31. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1
  32. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1
  33. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1
  34. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1
  35. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1
  36. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1
  37. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1
  38. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1
  39. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1
  40. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1
  41. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1
  42. Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1
  43. Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1
  44. Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Astex Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Boston Biomedical Inc
  • Calithera Biosciences Inc
  • Celldex Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • CytRx Corp
  • Deciphera Pharmaceuticals LLC
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co Ltd
  • Natco Pharma Ltd
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • Omeros Corp
  • Pharma Mar SA
  • Plexxikon Inc
  • Rhizen Pharmaceuticals SA
  • Taiho Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll